144 related articles for article (PubMed ID: 21504330)
21. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy?
Soulières D
Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapy in the treatment of metastatic renal cell cancer.
Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
24. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.
Bex A; Powles T
Expert Rev Anticancer Ther; 2012 Jun; 12(6):787-97. PubMed ID: 22716495
[TBL] [Abstract][Full Text] [Related]
25. Update on the medical treatment of metastatic renal cell carcinoma.
Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
[TBL] [Abstract][Full Text] [Related]
27. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
28. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
Shinohara N
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recurrent or metastatic renal cell carcinoma.
Shah RN; Ahmad T; Eisen TG
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1069-80. PubMed ID: 15606334
[TBL] [Abstract][Full Text] [Related]
30. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
31. New drug therapies for advanced renal cell carcinoma.
Gore ME; Harrison ML; Montes A
Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
[TBL] [Abstract][Full Text] [Related]
32. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
33. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
Shuuin T; Karashima H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
[TBL] [Abstract][Full Text] [Related]
34. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy of metastatic renal cancer.
Denis L; Van Oosterom A
Semin Surg Oncol; 1988; 4(2):91-4. PubMed ID: 3293156
[TBL] [Abstract][Full Text] [Related]
36. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
Kirkali Z
BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
[TBL] [Abstract][Full Text] [Related]
37. Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma.
Porta C; Bellmunt J; Eisen T; Szczylik C; Mulders P
Cancer Treat Rev; 2010 Feb; 36(1):16-23. PubMed ID: 19819078
[TBL] [Abstract][Full Text] [Related]
38. New treatment approaches in renal cell carcinoma.
Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
[TBL] [Abstract][Full Text] [Related]
39. Update on novel agents in renal cell carcinoma.
Tamaskar I; Pili R
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
[TBL] [Abstract][Full Text] [Related]
40. Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).
Haberkorn BC; Eskens FA
Future Oncol; 2013 Jan; 9(1):13-20. PubMed ID: 23252559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
